Wei Guo Su

Chief Executive Officer at HUTCHMED (CHINA) LIMITED

Net worth: 16 M $ as of 2024-03-30

66 year

Health Technology

Consumer Services

Profile

Currently, Wei Guo Su holds the position of Executive Director & Chief Scientific Officer at Hutchison China MediTech Ltd. and Chief Scientific Officer & Executive VP at Hutchison MediPharma Ltd. In his past career Dr. Su occupied the position of Director-Medicinal Chemistry Department at Pfizer Inc. He received a doctorate from Harvard University and an undergraduate degree from Fudan University.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
HUTCHMED (CHINA) LIMITED 0.53%	2024-03-12	4,653,040 ( 0.53% )	16 M $	2024-03-30

Wei Guo Su active positions

Companies	Position	Start
HUTCHMED (CHINA) LIMITED	Chief Executive Officer	2022-03-03
Hutchison MediPharma Ltd. Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China.	Chief Tech/Sci/R&D Officer	2010-03-23

All active positions of Wei Guo Su

Former positions of Wei Guo Su

Companies	Position	End
PFIZER, INC.	Corporate Officer/Principal	-

See the detail of Wei Guo Su's experience

Training of Wei Guo Su

Harvard University	Doctorate Degree
Fudan University	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Wei Guo Su's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
PFIZER, INC.	Health Technology
HUTCHMED (CHINA) LIMITED	Health Technology

Private companies	1
Hutchison MediPharma Ltd. Hutchison MediPharma Ltd. Medical SpecialtiesHealth Technology Hutchison MediPharma Ltd. discovers and develops innovative human therapeutics. Its products include savolitinib, fruqnitinib, sulfatinib, HMPL-523, epitinib, theliatinib, HMPL-453, HMPL-689 and HMPL-004. The company was founded by Ying Samantha Du in September 2002 and is headquartered in Shanghai, China.	Health Technology

See company connections